应对 COVID-19 大流行期间的变应原免疫治疗：ARIA-EAACI 立场声明。
Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement.
机构信息
Center for Rhinology and Allergology, Wiesbaden, Germany.
Department of Clinical Immunology, Wrocław Medical University, ALL-MED Medical Research Institute, Wrocław, Poland.
出版信息
Allergy. 2020 Jul;75(7):1546-1554. doi: 10.1111/all.14336.
Abstract
[Image: see text]
摘要
[图片：见正文]
相似文献
1
Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement.应对 COVID-19 大流行期间的变应原免疫治疗：ARIA-EAACI 立场声明。
Allergy. 2020 Jul;75(7):1546-1554. doi: 10.1111/all.14336.
2
Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines.利用T细胞免疫开发快速、安全且有效的新冠疫苗。
Expert Rev Vaccines. 2020 Sep;19(9):781-784. doi: 10.1080/14760584.2020.1825946. Epub 2020 Oct 6.
3
Vaccine Development Against COVID-19 Prior to Pandemic Outbreaks, Using Evolution and Reverse Genetics.在大流行爆发前利用进化和反向遗传学开发针对2019冠状病毒病的疫苗
Front Immunol. 2020 Aug 14;11:2051. doi: 10.3389/fimmu.2020.02051. eCollection 2020.
4
Developing Covid-19 Vaccines at Pandemic Speed.以大流行速度研发新冠疫苗。
N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.
5
Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study.过敏疾病与 COVID-19 的易感性和严重程度：一项全国性队列研究。
J Allergy Clin Immunol. 2020 Oct;146(4):790-798. doi: 10.1016/j.jaci.2020.08.008. Epub 2020 Aug 15.
6
Will bacille Calmette-Guerin immunization arrest the COVID-19 pandemic?卡介苗免疫接种能阻止新冠疫情吗？
Indian J Med Res. 2020;152(1 & 2):16-20. doi: 10.4103/ijmr.IJMR_1563_20.
7
Human papillomavirus: The other invisible enemy.人乳头瘤病毒：另一个隐形的敌人。
Gynecol Oncol. 2020 Aug;158(2):254-255. doi: 10.1016/j.ygyno.2020.05.024. Epub 2020 Jun 6.
8
COVID-19 in Africa: Dampening the storm?非洲的新冠疫情：平息风暴？
Science. 2020 Aug 7;369(6504):624-626. doi: 10.1126/science.abd3902.
9
[Not Available].[无可用内容]
Rev Med Suisse. 2020 Jun 3;16(696):1174-1175.
10
Vaccines targeting SARS-CoV-2 tested in humans.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的疫苗已在人体中进行了测试。
Nat Med. 2020 Sep;26(9):1336-1338. doi: 10.1038/s41591-020-1048-4.
引用本文的文献
1
Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children:a retrospective cohort study.新型冠状病毒肺炎对儿童皮下特异性免疫治疗不良反应的影响：一项回顾性队列研究
BMC Infect Dis. 2024 Aug 7;24(1):794. doi: 10.1186/s12879-024-09702-5.
2
Transition between subcutaneous and sublingual allergen immunotherapy: Recommendations of the Brazilian Association of Allergy and Immunology (ASBAI).皮下和舌下变应原免疫疗法之间的转换：巴西变态反应与免疫学协会（ASBAI）的建议。
J Allergy Clin Immunol Glob. 2024 May 18;3(3):100281. doi: 10.1016/j.jacig.2024.100281. eCollection 2024 Aug.
3
Safety and adverse reactions in subcutaneous allergen immunotherapy: a review.皮下变应原免疫治疗的安全性和不良反应：综述。
Acta Biomed. 2023 Aug 3;94(4):e2023172. doi: 10.23750/abm.v94i4.14239.
4
The relationship between sublingual immunotherapy for allergic rhinitis and the risk of symptoms in patients with COVID-19 infection.舌下免疫疗法治疗变应性鼻炎与 COVID-19 感染患者症状风险之间的关系。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2236538. doi: 10.1080/21645515.2023.2236538.
5
Aeroallergen immunotherapy associated with reduced risk of severe COVID-19 in 1095 allergic patients.在1095名过敏患者中，空气过敏原免疫疗法与降低严重COVID-19风险相关。
World Allergy Organ J. 2023 May;16(5):100779. doi: 10.1016/j.waojou.2023.100779. Epub 2023 May 3.
6
Clinical endpoints in allergen immunotherapy: State of the art 2022.变应原免疫治疗的临床终点：2022年最新进展
Allergol Select. 2023 Mar 1;7:39-46. doi: 10.5414/ALX02334E. eCollection 2023.
7
Deciphering Differential Behavior of Immune Responses as the Foundation for Precision Dosing in Allergen Immunotherapy.解析免疫反应的差异行为作为变应原免疫治疗精准给药的基础。
J Pers Med. 2023 Feb 13;13(2):324. doi: 10.3390/jpm13020324.
8
111 years of allergen-immunotherapy: A long and successful history of the only available disease-modifier in allergic diseases.111年的变应原免疫疗法：这是过敏性疾病中唯一可用的疾病改良疗法漫长且成功的历史。
Allergol Select. 2022 Nov 21;6:248-258. doi: 10.5414/ALX02330E. eCollection 2022.
9
Allergic diseases and immunodeficiencies in children, lessons learnt from COVID-19 pandemic by 2022: A statement from the EAACI-section on pediatrics.儿童变态反应性疾病和免疫缺陷，2022 年从 COVID-19 大流行中吸取的教训：EAACI 儿科分会的声明。
Pediatr Allergy Immunol. 2022 Oct;33(10):e13851. doi: 10.1111/pai.13851.
10
SARS-CoV-2 Infection (COVID-19) and Rhinologic Manifestation: Narrative Review.严重急性呼吸综合征冠状病毒2感染（COVID-19）与鼻科表现：叙述性综述
J Pers Med. 2022 Jul 28;12(8):1234. doi: 10.3390/jpm12081234.
本文引用的文献
1
Functional exhaustion of antiviral lymphocytes in COVID-19 patients.新冠病毒肺炎患者抗病毒淋巴细胞的功能耗竭
Cell Mol Immunol. 2020 May;17(5):533-535. doi: 10.1038/s41423-020-0402-2. Epub 2020 Mar 19.
2
Eleven faces of coronavirus disease 2019.2019 年冠状病毒病的 11 个面孔。
Allergy. 2020 Jul;75(7):1699-1709. doi: 10.1111/all.14289. Epub 2020 Apr 6.
3
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
4
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
5
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.严重急性呼吸综合征相关冠状病毒：将 2019-nCoV 进行分类并命名为 SARS-CoV-2。
Nat Microbiol. 2020 Apr;5(4):536-544. doi: 10.1038/s41564-020-0695-z. Epub 2020 Mar 2.
6
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.COVID-19 的免疫反应和潜在疫苗：从 SARS 和 MERS 疫情中吸取的教训。
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9. doi: 10.12932/AP-200220-0772.
7
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.中国武汉 140 名 SARS-CoV-2 感染患者的临床特征。
Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.
8
Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes.2019-nCoV 感染患者的分子和血清学调查：多种脱落途径的意义。
Emerg Microbes Infect. 2020 Feb 17;9(1):386-389. doi: 10.1080/22221751.2020.1729071. eCollection 2020.
9
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
10
Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany.德国一名无症状接触者传播2019新型冠状病毒感染
N Engl J Med. 2020 Mar 5;382(10):970-971. doi: 10.1056/NEJMc2001468. Epub 2020 Jan 30.
Zotero 插件